An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arbutus Biopharma (Nasdaq: ABUS) will report its first quarter 2024 financial results and provide a corporate update on May 2, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection.
Arbutus Biopharma (Nasdaq: ABUS) comunicherà i risultati finanziari del primo trimestre del 2024 e fornirà un aggiornamento aziendale il 2 maggio 2024. L'obiettivo dell'azienda è sviluppare una cura funzionale per l'infezione cronica del virus dell'epatite B.
Arbutus Biopharma (Nasdaq: ABUS) informará sobre sus resultados financieros del primer trimestre de 2024 y proporcionará una actualización corporativa el 2 de mayo de 2024. La compañía tiene como objetivo desarrollar una cura funcional para la infección crónica del virus de la hepatitis B.
Arbutus Biopharma (나스닥: ABUS)는 2024년 5월 2일에 2024년도 1분기 재무 결과를 보고하고 기업 업데이트를 제공할 예정입니다. 이 회사는 만성 B형 간염 바이러스 감염에 대한 기능적 치료법을 개발하고자 합니다.
Arbutus Biopharma (Nasdaq: ABUS) communiquera ses résultats financiers du premier trimestre 2024 et fournira une mise à jour de l'entreprise le 2 mai 2024. La société vise à développer un traitement fonctionnel pour l'infection chronique par le virus de l'hépatite B.
Arbutus Biopharma (Nasdaq: ABUS) wird am 2. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 bekannt geben und ein Unternehmensupdate bereitstellen. Das Unternehmen zielt darauf ab, eine funktionelle Heilung für die chronische Hepatitis-B-Virusinfektion zu entwickeln.
Positive
None.
Negative
None.
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows:
•
Q1 2024 Press Release:
Thursday, May 2, 2024 at 7:30 a.m. ET
•
Q1 2024 Conference Call/Webcast:
Thursday, May 2, 2024 at 8:45 a.m. ET
To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli Vice President, Investor Relations Phone: 215-206-1822 Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma report its first quarter 2024 financial results?
Arbutus Biopharma will report its first quarter 2024 financial results on Thursday, May 2, 2024, at 7:30 a.m. ET.
What is the ticker symbol for Arbutus Biopharma ?
The ticker symbol for Arbutus Biopharma is ABUS.
Where can I access the live webcast of the conference call for Arbutus Biopharma ?
You can access the live webcast of the conference call for Arbutus Biopharma through the Investors section of their website at www.arbutusbio.com.
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
